Sells it 4%, $1.5B a year“TEZSPIRE is currently approved for the treatment of severe uncontrolled asthma (SUA) in the United States, Europe, Japan and more than 70 countries across the globe.”
Latest 10-KFY2025Impairment / charge ·
Repatha and TEZSPIRE growth outweighed ENBREL’s price-led decline; Prolia and XGEVA biosimilars threaten faster erosion.
Revenue$36.8BYoY +10.0%
Net income$7.7BYoY +88.5%
Latest 10-QQ3 FY2026 ·
Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.
Revenue$10.4BYoY +8.5%
Net income$3.9BYoY +20.1%
Latest 8-KPositiveEarningsGuidance raised ·
Repatha and IMDELLTRA sales surge as biosimilars hit Prolia and XGEVA; FY2026 revenue outlook rises to $38.9B–$39.7B.
Latest 8-KLeadership change ·
Former Yum! Brands CEO David Gibbs joins the board, bringing direct customer relationship experience to inform future product launches
Latest 8-KCybersecurity incident ·
Third-party cloud data theft deemed material due to file volume and potential sensitivity, including proprietary and patient health information
Latest 8-KShareholder vote ·
Shareholders rejected a requirement for an independent board chairman and elected all director nominees.
Latest 8-KCEO/CFO change ·
Thomas Dittrich returns from Galderma to succeed retiring CFO Peter Griffith, who stays through January 2027 to support the transition.
Latest 8-KDebt financing ·
Issues senior unsecured notes across four tranches, with maturities extending to 2056.
In development“Our first phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa (“ P. aeruginosa”) .”
Convertible-loan fair-value losses drove the net loss; Innoviva credit maturities were extended amid a going-concern warning.
Latest 8-KDebt financingGovernance change ·
Innoviva subsidiary extends credit maturities and warrant expirations; FDA approval of a product candidate now triggers early termination of the voting agreement.
In development“We are currently evaluating BBT002 for the treatment of chronic obstructive pulmonary disease (“COPD”) in our global Phase 1 clinical trial in the United States, Australia, Europe, Georgia, and New Zealand (“Global BBT002 Study”) and our Phase 1/2a clinical trial for COPD in China (“China COPD Study”).”
Sells it 57%, $236.5M a year“In November 2002, we entered into our LABA Collaboration Agreement with GSK to develop and commercialize once‑daily products for the treatment of chronic obstructive pulmonary disease (“COPD”) and asthma.”
Latest 10-KFY2025Positive ·
GIAPREZA and XACDURO lifted product sales, but at-cost Zai Lab supply limited margins; Armata investment gains drove GAAP earnings.
Revenue$411.3MYoY +14.7%
Net income$271.2Mvs $23.4M year ago
Latest 10-QQ3 FY2026Positive ·
XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings
Revenue$106.1MYoY −1.6%
Net income−$73.9Mvs $89.9M year ago
Latest 8-KEarningsGuidance reaffirmed ·
Lower royalties and ex-U.S. sales timing weighed on revenue; $139.5M in investment markdowns, mainly Armata, drove the net loss.
Latest 8-KLeadership change ·
Derek Small and Mark DiPaolo resign from the board to grow Syndeio BioSciences; Josephine Linden joins.
Latest 8-KShareholder voteExecutive pay ·
Stockholders approved the 2026 Equity Incentive Plan and elected five directors to one-year terms.
Supplies it“In 2019, the FDA cleared our Ion endoluminal system, which is a flexible, robotic-assisted, catheter-based platform that utilizes instruments and accessories for which the first cleared indication is minimally invasive biopsies in the lung.”
Latest 10-KFY2025 ·
Intuitive Surgical delivered broad-based FY2025 growth as rising procedure volumes expanded recurring revenue and da Vinci 5 accelerated system placements. Revenue increased 21% and operating income increased 25%, despite lower gross margins from tariffs, new-system costs, manufacturing expansion, and service repairs. The investment case rests on converting a larger installed base into sustained…
da Vinci antitrust settlement drives a $450M charge and GAAP profit decline despite procedure and lease growth
Latest 8-KGovernance change ·
Bylaws tighten shareholder nomination and proxy rules; non-director-election actions shift to majority of votes cast, excluding abstentions and broker non-votes.
Latest 8-KBuybackExecutive payShareholder vote ·
Board expands buyback authorization to $5.0B; stockholders extend the incentive plan and increase its share reserve.
Latest 8-KPositiveDeal completed ·
Acquisition of da Vinci and Ion distributors expands direct operations in Italy, Spain and Portugal.
Sells it <1%, $178.0M a year“Ohtuvayre (ensifentrine), an inhaled PDE3/4 inhibitor indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.”
Latest 10-KFY2025Restructuring ·
China Gardasil inventory overhang blunted Keytruda and Winrevair growth; launches and acquisitions seek replacement revenue.
Revenue$65.0BYoY +1.3%
Net income$18.3BYoY +6.6%
Latest 10-QQ3 FY2026Impairment / charge ·
Keytruda Qlex offsets IV declines; purchase timing lifts sales as pipeline acquisitions weigh on earnings.
Revenue$18.1BYoY +4.7%
Net income$5.1BYoY −12.4%
Latest 8-KLeadership change ·
Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.
In development“ARDS is a respiratory condition in which patients’ lungs are compromised, and they cannot imbibe enough oxygen through normal inhalation.”